A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 23, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Stomach Neoplasm
Interventions
DRUG

Docetaxel injection, oxaliplatin, S-1

As a prior chemotherapy, intravenous administration is performed every 3 weeks for docetaxel 50 mg/m2 D1, intravenous administration for oxaliplatin 100 mg/m2 D1, and oral administration twice a day for S-140 mg/m2 D1 to 14.

Trial Locations (1)

138-736

RECRUITING

Asan Medical Center, University of Ulsan College of Medicine, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT05184803 - A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer | Biotech Hunter | Biotech Hunter